A vaccine platform developed from a synthetic polymeric glyco-adjuvant and reversibly conjugated to an antigen was shown to target dendritic cells leading to cellular and humoral immune response against malaria.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Seder, R. et al. Vaccine 33, B40–B43 (2015).
Wilson, D. S. et al. Nat. Mater. https://doi.org/10.1038/s41563-018-0256-5 (2018).
Steinman, R. M. & Banchereau, J. Nature 449, 419–426 (2007).
Lambrecht, B. N., Kool, M., Willart, M. A. M. & Hammad, H. Curr. Opin. Immunol. 21, 23–29 (2011).
Idoyaga, J. et al. Proc. Natl Acad. Sci. USA 108, 2384–2389 (2011).
Burgdorf, S., Kautz, A., Böhnert, V., Knolle, P. A. & Kurts, C. Science 316, 612–616 (2007).
Kashem, S. W., Haniffa, M. & Kaplan, D. H. Annu. Rev. Immunol. 35, 469–499 (2017).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
van Kooyk, Y. Next-generation malarial vaccines. Nature Mater 18, 94–96 (2019). https://doi.org/10.1038/s41563-018-0267-2
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41563-018-0267-2
